Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database

Authors

Kristin J. Meyers, Eli Lilly and Company
Jonathan I. Silverberg, The George Washington University
Maria Jose Rueda, Eli Lilly and Company
Robert Goodloe, Eli Lilly and Company
Evangeline J. Pierce, Eli Lilly and Company
Walter Deberdt, Eli Lilly Benelux
Dennis R. Brinker, Eli Lilly and Company

Document Type

Journal Article

Publication Date

6-1-2021

Journal

Dermatology and Therapy

Volume

11

Issue

3

DOI

10.1007/s13555-021-00538-4

Keywords

Atopic dermatitis; Risk factors; Venous thromboembolism

Abstract

Introduction: Atopic dermatitis (AD) is associated with risk factors for venous thromboembolism (VTE). However, the risk of VTE among this population is unknown. The aim of this study was to assess the risk of VTE among adults with AD and compare the risk vs. matched non-AD controls. Methods: This retrospective study used claims data from the IBM Watson MarketScan® Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases to identify adults aged 18 years or older with AD. Incidence rates (IR) per 100 person-years (PY) of VTE were reported for three cohorts: overall AD, moderate-to-severe AD, and non-AD controls matched by age, sex, and calendar time to the overall cohort. Cox proportional hazards regression was used to estimate hazard ratios (HR) for VTE risk. Results: Overall, 198,685 patients with AD were identified. Crude VTE IRs were 0.24 for AD overall, 0.31 for moderate-to-severe AD, and 0.25 for non-AD controls. VTE risk was similar in patients with AD vs. non-AD controls (partially adjusted HR 1.00, 95% confidence interval [CI] 0.92, 1.09). VTE risk was greater in patients with moderate-to-severe AD vs. non-AD controls in partially adjusted models (HR 1.24, 95% CI 1.13, 1.36), but not after adjustment for healthcare use and VTE risk factors (HR 0.95, 95% CI 0.85, 1.07). Conclusions: AD was not an independent risk factor for VTE, and the risk of VTE among patients with AD was low. These findings provide valuable context for understanding VTE risk among patients with AD, which is particularly relevant as advanced therapies for the treatment of moderate to severe AD, such as janus kinase inhibitors, become available.

APA Citation

Meyers, K., Silverberg, J., Rueda, M., Goodloe, R., Pierce, E., Deberdt, W., & Brinker, D. (2021). Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database. Dermatology and Therapy, 11 (3). http://dx.doi.org/10.1007/s13555-021-00538-4